Skip to content

Psilocybin: all studies

Page 351 of 441: studies 3,501 to 3,510 of 4,401, newest first. Back to the psilocybin overview

Research

The Interconnection of Psychedelic Spirituality, Social Justice, and BIPOC Therapist Engagement in Psychedelic-Assisted Therapy: Insights from the Psychedelic Therapists Diversity Study

Psychedelic Intersections January 17, 2025 Candace Oglesby, Yvan Beaussant

This paper presents insights from the Psychedelic Therapists Diversity (PTD) study, a qualitative study conducted to understand how BIPOC therapists perceive psychedelic therapy and research. The inciting incident for this research occurred during our collaboration on a clinical trial of psilocybin-assisted therapy for depression in cancer patients.1 Candace Oglesby was the only therapist of...

Psychedelic-related deaths in England, Wales and Northern Ireland (1997-2022).

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 10, 2025 Emma I Kopra, Jenni Penttinen, James J Rucker et al. 9 citations

Psychedelic drugs are increasingly visible in society once more, but their risks and adverse effects have received less attention than perhaps they should. While fatalities associated with psychedelics appear rare, a systematic approach to characterising their aetiology is required to inform harm minimisation efforts. This study aimed to analyse prevalence and characteristics of...

DOI: 10.1016/j.pnpbp.2024.111177 (opens in new tab) Full text (opens in new tab) Psychedelics hallucinogens Entheogens Psychedelic drugs Pharmaceutical safety +7

Social pain: A systematic review on interventions

F1000Research January 10, 2025 Brandon M. Brooks, Francisco J. Cordero, Stephen L. Alchermes et al. 3 citations

Social pain is emotional distress caused by harm or threat to social connections that results in social exclusion, rejection, or loss. Social Pain is also a potentiator of physical pain. Supportive social relationships are widely recognized for their impact on maintaining health and well-being. The Passion of Jesus Christ serves as a quintessential example of social pain (i.e., desertion,...

DOI: 10.12688/f1000research.159561.1 (opens in new tab) Psychological intervention Systematic review Randomized controlled trial Psychotherapist +2

PSYCHEDELICS IN THE TREATMENT OF MENTAL DISORDERS

Health and Society January 8, 2025 Eduardo D’avila Lins Lacerda, Bianca Medeiros Ferraz da Nóbrega, Yasmin Mesquita Dias Franca Gadelha et al.

Psychedelics have emerged as a promising approach to treating mental disorders, challenging traditional paradigms in psychiatry. This study conducted an integrative literature review to investigate the advances, challenges, and implications of the therapeutic use of these substances, addressing the guiding question: “What are the current scientific perspectives on the use of psychedelics in the...

Molecular Phylogeny and Morphology Reveal Four New Species of Conocybe (Bolbitiaceae, Agaricales) from the Qinghai-Xizang Plateau, China

Journal of Fungi January 7, 2025 Xi-Xi Han, Dorji Phurbu, Bin Cao et al. 2 citations

The Qinghai-Xizang Plateau, known for its high altitude, geological history of plate collision, crustal uplift, and special ecology factors, provides an ideal environment for studying fungal biodiversity in extreme environmental conditions. Some species within the Conocybe, containing secondary metabolites such as psilocybin, phallotoxins, and amatoxins, have potential medicinal value for...

DOI: 10.3390/jof11010045 (opens in new tab) Fungi taxonomy Biodiversity research Alpine ecosystems Bolbitiaceae +5

Psychedelic Treatments in Adolescent Psychopharmacology: Considering Safety, Ethics, and Scientific Rigor

Journal of Child and Adolescent Psychopharmacology January 6, 2025 Isabella Sutherland, Ming-Fen Ho, Paul E Croarkin 10 citations

Interest in psychedelic therapies for adults is rapidly growing, with substances like 3,4-methylenedioxymethamphetamine for posttraumatic stress disorder, psilocybin for treatment-resistant depression, and lysergic acid diethylamide for generalized anxiety disorder showing promise. However, research on these therapies in children and adolescents is limited, with no recent trials. Despite this...

DOI: 10.1089/cap.2024.0082 (opens in new tab) Psychopharmacology Rigour Psychotherapist Engineering ethics +1

In Silico Evaluation of Tryptamine-Derived Schiff Bases as Modulators of the Serotonin 5-HT₂A Receptor

Book of Proceedings 2025 Marina D. Kostić, Jana Nedić, Jovana S. Dragojević et al.

Serotonin receptors, also known as 5-hydroxytryptamine (5-HT) receptors, are a diverse family of G protein-coupled and ligand-gated ion channel receptors that mediate the physiological effects of the neurotransmitter serotonin. These receptors are widely distributed throughout the central and peripheral nervous systems, where they regulate numerous processes including mood, cognition,...

Fighting Drugs with Drugs: Medical Mushrooms in Utah's War on Opioids

Utah law review 2025 Paul Helms

In addition to the happy side effect of improving psilocybin’s odds of rescheduling under the proposed new CAMU standard (potentially increasing national psilocybin accessibility for opioid recovery), Senator Escamilla’s S.B. 200 could represent the beginning of a new era for the State of Utah in its battle against opioids. Despite S.B. 200’s failure to pass, the medical application of...

High hopes? Precision psychedelic addiction medicine.

Frontiers in Psychiatry 2025 Rayyan Raja Zafar, Patrick Kleine, Danielle Kurtin et al.

Despite decades of neuroscience research and significant investment in addiction neuroimaging, clinical outcomes for individuals with substance use and behavioural addictions remain poor. Only 1.8% of people with substance use disorders receive effective treatment, highlighting a major disconnect between mechanistic understanding and clinical utility. This paper calls for a reorientation of...